Trial · NCT05395507
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia
NCT05395507, Phase 2, Unknown, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia. Trials, record NCT05395507. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05395507
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia
- NCT number
- NCT05395507
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 194 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Essential Thrombocytopenia
- Interventions
- Recombinant Interferon Alpha, Pegylated interferon alfa-2b
- First posted
- 2022-05-27
- Last updated
- 2024-07-03
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete hematological remission (CHR) rates | From the start of study treatment (Week 0) up to the end of Week 52 | The CHR rates defined as European Leukemia Net will be compared between the two groups. |
| Secondary | CHR rates at week 24 and 36 | From the start of study treatment (Week 0) up to the end of Week 24 and Week 36, respectively | The CHR rates at week 24 and 36 will be compared between the two groups |
| Secondary | Time to CHR | From the start of study treatment (Week 0) up to the end of Week 52. | The time of reaching CHR will be compared between the two groups |
| Secondary | The proportion of patients crossed to the contralateral group | From the start of study treatment (Week 0) up to the end of Week 52. | The proportion of patients crossed to the contralateral group will be compared between the two groups |
| Secondary | The CHR rates after crossover | From the start of study treatment (Week 0) up to the end of Week 52. | The CHR rates within 52 weeks after crossover |
| Secondary | Impact of therapy on driver mutations | From the start of study treatment (Week 0) up to the end of Week 52. | To compare the proportion of subjects that display change on key biomarkers of the disease- JAK2V617F, CALR, MPL mutations. |
| Secondary | Impact of therapy on non-driver mutations | From the start of study treatment (Week 0) up to the end of Week 52. | To compare the proportion of subjects that display change on key non-driver biomarkers of the disease-DNMT3A, ASXL1, TET2 or other mutations. |
| Secondary | Change of splenomegaly | From the start of study treatment (Week 0) up to the end of Week 52. | To compare the proportion of subject with improvement and no progress rate of splenomegaly between the two groups. |
| Secondary | Change of bone marrow pathology | From the start of study treatment (Week 0) up to the end of Week 52. | To compare the rate of patients with improvement and no progress rate of bone marrow pathology between the two groups |
| Secondary | The incidence of major thrombotic events | From the start of study treatment (Week 0) up to the end of Week 52. | To compare the incidence of major thrombotic events between the two groups. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05395507
GET https://conductscience.org/api/trials/v1/NCT05395507/registered